New Covid Variant PJ.2.1 Spreads Globally, Underscoring Persistent Viral Threat

A new strain of Covid-19, identified as PJ.2.1, is currently spreading worldwide, serving as a stark reminder of the virus's persistent and evolving threat, nearly seven years after its initial emergence. While doctors indicate that PJ.2.1 does not appear to be significantly more harmful than other recent strains, it is becoming responsible for a larger proportion of infections. Although Covid-19 is no longer causing the same levels of severe illness or death seen in the early stages of the pandemic, it continues to pose a risk to vulnerable populations.

Globally, approximately 780 million infections and seven million deaths have been linked to Covid-19 to date, with a notable decline in new cases. In the 28-day period leading up to October 18, a total of 56,471 new infections were reported, a decrease of over 35,000 from the preceding month. Since its identification in May in North America, PJ.2.1 has demonstrated "rapid intercontinental spread," according to a September study by Chinese scientists. This research also suggested that PJ.2.1 is more effective than other variants at binding to ACE2, the receptor the virus uses to enter cells. A subsequent study released last month proposed that this enhanced ACE2 binding capability could be driving the variant's swift global dissemination.

The World Health Organisation has stated that PJ.2.1, similar to previous variants, presents symptoms comparable to the common cold or influenza. Wam, the official UAE news agency, quoted Professor Elena Malinnikova of the Russian Medical Academy of Continuing Professional Education, who noted that PJ.2.1 might lead to more severe throat infections and potentially more prolonged fatigue compared to other variants. Despite PJ.2.1 possessing numerous mutations on its spike protein, the structure the virus uses to attach to cells, it is not believed to be more adept at evading the human immune system.

Dr. Asher Jamal, an emergency physician at NMC Royal Hospital Sharjah, advised against excessive alarm regarding the spread of new variants. He stated, "New variants will continue to emerge but so far there’s no convincing evidence that recent variants are causing more severe illness, need a different treatment regimen or pose an imminent threat." He added, "We still need to keep an eye on them but I don’t think there’s a reason for unnecessary alarm." Dr. Jamal observed that while Covid is still present, hospitals are not experiencing the same severity or strain on healthcare services as during the pandemic. He clarified that most cases are now relatively mild, though the elderly and immunocompromised remain susceptible to serious complications, and life-threatening pneumonia and long-term complications are not frequently encountered in emergency departments.

PJ.2.1 was first identified in Ontario, Canada, in early May of this year and was subsequently detected in New York, USA, at the end of June. It has since spread to numerous other US states, where it is reportedly the fastest-growing Covid-19 variant in terms of case numbers. Highlighting its global reach, PJ.2.1 has also been detected in Australia, Singapore, and Spain.

Echoing these sentiments, Professor Paul Hunter, an infectious diseases specialist and professor of medicine at the University of East Anglia in the UK, noted that PJ.2.1 appears to be increasing in proportion among infections. "There doesn’t seem to be evidence it causes more severe disease, higher hospitalisation rates or greater mortality than other circulating variants," he commented. However, he cautioned that predicting the future behavior of new variants with certainty is not possible. Despite the overall decline in numbers compared to previous years, he acknowledged that Covid-19 continues to hospitalize individuals.

Professor Eskild Petersen, who previously chaired the emerging infections task force of the European Society of Clinical Microbiology and Infectious Diseases, indicated that vaccinations provide substantial protection for most individuals against Covid-19. He added that the new variant, despite its numerous mutations from other forms of Sars-CoV-2, will "most probably will also be picked up by the rapid test many people have at home." Professor Petersen, affiliated with the PandemicX Centre at Roskilde University in Denmark, also mentioned that while Sars-CoV-2 continues to mutate, it generally exhibits greater stability than influenza viruses. "There’s extensive cross-immunity between the different Covid lines," he explained, suggesting that infection with one variant may enhance a person's ability to combat subsequent infections with other variants.

Dr. Ali Alessandro Ayach, a UAE-based partner at the consultancy Arthur D Little specializing in the healthcare sector, commented that while Covid-19 is not currently straining hospitals as it did early in the pandemic, its lingering effects are still felt. "There’s a longer-term impact as some patients continue to experience health problems after recovering from Covid-19, even with the vaccination, and that’s creating some pressure on healthcare services and affecting their ability to return to normal," he stated. He emphasized the importance of developing healthcare systems capable of absorbing future pandemic shocks while maintaining routine care, which necessitates building adaptable capacity. "How do you manage respiratory infections alongside diabetes, cardiovascular diseases, cancer and growing demand for care?" he posed, highlighting the complex challenges ahead.